A phase II study of Givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy

British Journal of Haematology

Volumn 161, Issue 5, 2013, Pages 688-694

  Finazzi, Guido ^a   Vannucchi, Alessandro M ^b   Martinelli, Vincenzo ^c   Ruggeri, Marco ^d   Nobile, Francesco ^e   Specchia, Giorgina ^f   Pogliani, Enrico Maria ^g   Olimpieri, Odoardo Maria ^h   Fioritoni, Giuseppe ⁱ   Musolino, Caterina ^j   Cilloni, Daniela ^k   Sivera, Piera ^l   Barosi, Giovanni ^m   Finazzi, Maria Chiara ^a   Tollo, Silvia Di ⁿ   Demuth, Tim ⁿ   Barbui, Tiziano ^a   Rambaldi, Alessandro ^a  

^a PAPA GIOVANNI XXIII HOSPITAL   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c FEDERICO II UNIVERSITY HOSPITAL   (Italy)

^d SAN BORTOLO HOSPITAL   (Italy)

^e AO Bianchi Melacrino Morelli   (Italy)

^f POLICLINICO   (Italy)

^g SAN GERARDO HOSPITAL   (Italy)

^h UNIVERSITY CAMPUS BIO MEDICO   (Italy)

ⁱ Santo Spirito General Hospital   (Italy)

^j UNIVERSITY OF MESSINA   (Italy)

^k SAN LUIGI GONZAGA UNIVERSITY HOSPITAL   (Italy)

^l SCU Haematology   (Italy)

^m FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

ⁿ Italfarmaco SpA   (Italy)

more..

Author keywords

Givinostat; Histone deacetylase inhibitor; Hydroxycarbamide; Myeloproliferative neoplasm; Polycythaemia vera

Indexed keywords

GIVINOSTAT; HYDROXYUREA;

ADULT; AGED; ANEMIA; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DISEASE CONTROL; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEART ARRHYTHMIA; HUMAN; HYPERKALEMIA; MAGNESIUM BLOOD LEVEL; MALE; MULTICENTER STUDY; NAUSEA; PHASE 2 CLINICAL TRIAL; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PRURITUS; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME; UPPER ABDOMINAL PAIN;

ADULT; AGED; AGED, 80 AND OVER; CARBAMATES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXYUREA; MALE; MIDDLE AGED; NUCLEIC ACID SYNTHESIS INHIBITORS; POLYCYTHEMIA VERA; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 84877814233     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12332     Document Type: Article

References (30)

1. Akada, H., Hamada, S. & Mohi, M.G. (2010) Effficacy of vorinostat in a murine model of polycythemia vera. Blood, 116, 629.
2. Amaru Calzada, A., Todoerti, K., Donadoni, L., Pellicioli, A., Tuana, G., Gatta, R., Neri, A., Finazzi, G., Mantovani, R., Rambaldi, A., Introna, M., Lombardi, L. & Golay, J. (2012a) The HDAC inhibitor Givinostat modulates the hematopoietic transcription factors NFE2 and C-MYB in JAK2(V617F) myeloproliferative neoplasm cells. Experimental Hematology, 40, 634-635.
3. Amaru Calzada, A., Pedrini, O., Finazzi, G., Leoni, F., Mascagni, P., Introna, M., Rambaldi, A. & Golay, J. (2012b) Givinostat and hydroxyurea synergize in vitro to induce apoptosis of cells from JAK2(V617F) myeloproliferative neoplasm patients. Experimental Hematology, 42, 253-260.
4. Andersen, C.L., McMullin, M.F., Ejerblad, E., Zweegman, S., Harrison, C.N., Fernandes, S., Bareford, D., Knapper, S., Samuelsson, J., Lofvenberg, E., Linder, O., Andreasson, B., Ahlstrand, E., Jensen, M.K., Bjerrum, O.W., Vestergaard, H., Larsen, H., Klausen, T.W., Anderesen, T.M. & Hasselbalch, H.C. (2012) A phase II study of vorinostat (MK-0683) in patients with polycythemia vera and essential thrombocythemia. Blood, 120, 634.
5. Baffert, F., Evrot, E., Ebel, N., Roelli, C., Andraos, R., Qian, Z., Romanet, V., Murakami, M. & Radimerski, T. (2011) Improved efficacy upon combined JAK1/2 and pan-deacetylase inhibition using Ruxolitinib (INC424) and Panobinostat (LBH589) in preclinical mouse models of JAK2V617F-driven disease. Blood, 118, 798.
6. Barbetti, V., Gozzini, A., Rovida, E., Morandi, A., Spinelli, E., Fossati, G., Mascagni, P., Lübbert, M., Dello Sbarba, P. & Santini, V. (2008) Selective anti-leukaemic activity of low-dose histone deacetylase inhibitor ITF2357 on AML1/ETO-positive cells. Oncogene, 27, 1767-1778.
7. Barbui, T., Barosi, G., Birgegard, G., Cervantes, F., Finazzi, G., Griesshammer, M., Harrison, C., Hasselbalch, H.C., Hehlmann, R., Hoffman, R., Kiladjian, J.J., Kröger, N., Mesa, R., McMullin, M.F., Pardanani, A., Passamonti, F., Vannucchi, A.M., Reiter, A., Silver, R.T., Verstovsek, S. & Tefferi, A. (2011) Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. Journal of Clinical Oncology, 29, 761-770.
8. Barosi, G., Birgegard, G., Finazzi, G., Griesshammer, M., Harrison, C., Hasselbalch, H.C., Kiladjian, J.J., Lengfelder, E., McMullin, M.F., Passamonti, F., Reilly, J.T., Vannucchi, A.M. & Barbui, T. (2009) Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. Blood, 113, 4829-4833.
9. Barosi, G., Birgegard, G., Finazzi, G., Griesshammer, M., Harrison, C., Hasselbalch, H., Kiladijan, J.J., Lengfelder, E., Mesa, R., McMullin, M.F., Passamonti, F., Reilly, J.T., Vannucchi, A.M. & Barbui, T. (2010) A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process. British Journal of Haematology, 148, 961-963.
10. Carta, S., Tassi, S., Semino, C., Fossati, G., Mascagni, P., Dinarello, C.A. & Rubartelli, A. (2006) Histone deacetylase inhibitors prevent exocytosis of interleukin-1beta-containing secretory lysosomes: role of microtubules. Blood, 108, 1618-1626.
11. Dawson, M.A., Bannister, A.J., Gottgens, B., Foster, S.D., Bartke, T., Green, A.R. & Kouzarides, T. (2009) JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin. Nature, 461, 819-822.
12. Finazzi, G. & Barbui, T. (2007) How I treat patients with polycythemia vera. Blood, 109, 5104-5111.
13. Golay, J., Cuppini, L., Leoni, F., Micò, C., Barbui, V., Domenghini, M., Lombardi, L., Neri, A., Barbui, A.M., Salvi, A., Pozzi, P., Porro, G., Pagani, P., Fossati, G., Mascagni, P., Introna, M. & Rambaldi, A. (2007) The histone deacetylase inhibitor ITF2357 has anti-leukemic activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal cells. Leukemia, 21, 1892-1900.
14. Guerini, V., Barbui, V., Spinelli, O., Salvi, A., Dellacasa, C., Carobbio, A., Introna, M., Barbui, T., Golay, J. & Rambaldi, A. (2008) The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F). Leukemia, 22, 740-747.
15. Harrison, C., Kiladijan, J.J., Al-Ali, H.K., Gisslinger, H., Waltzman, R., Stalbovskaya, V., McQuitty, M., Hunter, D.S., Levy, R., Knoops, L., Cervantes, F., Vannucchi, A.M., Barbui, T. & Barosi, G. (2012) JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. New England Journal of Medicine, 366, 787-798.
16. He, J. & Zhang, Y. (2010) Janus Kinase 2: an epigenetic 'writer' that activates leukemogenic genes. Journal of Molecular Cell Biology, 2, 231-233.
17. Kramer, O.H., Knauer, S.K., Zimmermann, D., Stauber, R.H. & Heinzel, T. (2008) Histone deacetylase inhibitors and hydroxyurea modulate the cell cycle and cooperatively induce apoptosis. Oncogene, 27, 732-740.
18. Mascarenhas, J., Mercado, A., Rodriguez, A., Lu, M., Kalvin, C., Li, X., Petersen, B., Najfeld, V., Goldberg, J.D. & Hoffman, R. (2011) Prolonged low-dose therapy with a pan-deacetylase inhibitor, panobinostat (LBH589), in patients with myelofibrosis. Blood, 118, 794.
19. Pardanani, A., Gotlib, J.R., Jamieson, C., Cortes, J.E., Talpaz, M., Stone, R.M., Silverman, M.H., Gilliland, D.G., Shorr, J. & Tefferi, A. (2011) Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. Journal of Clinical Oncology, 29, 789-796.
20. Quintas-Cardama, A., Kantarijan, H.M., Borthakur, G., Estrov, Z., Cortes, J.E. & Verstovsek, S.l. (2011) Therapy with the histone deacetylase inhibitor Sb939 for patients with myelofibrosis. Blood, 118, 3863.
21. Rambaldi, A., Dellacasa, C.M., Finazzi, G., Carobbio, A., Ferrari, M.L., Guglielmelli, P., Gattoni, E., Salmoiraghi, S., Finazzi, M.C., Di Tollo, S., D'Urzo, C., Vannucchi, A.M., Barosi, G. & Barbui, T. (2010) A pilot study of the Histone-Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms. British Journal of Haematology, 150, 446-455.
22. Saini, K.S., Patnaik, M.M. & Tefferi, A. (2010) Polycythemia vera-associated pruritus and its management. European Journal of Clinical Investigation, 40, 828-834.
23. Simon, R., Thall, P.F. & Ellenberg, S.S. (1994) New designs for the selection of treatment to be tested in randomized clinical trials. Statistics in Medicine, 13, 417-429.
24. Tefferi, A. (2012) JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths. Blood, 119, 2721-2730.
25. Tefferi, A. & Vardiman, J.W. (2008) Classification and diagnosis of myeloproliferative neoplasm: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia, 22, 14-22.
26. Vannucchi, A.M., Guglielmelli, P., Rambaldi, A., Bogani, C. & Barbui, T. (2009) Epigenetic therapy in myeloproliferative neoplasms: evidence and perspectives. Journal of Cellular and Molecular Medicine, 13, 1437-1450.
27. Verstovsek, S., Passamonti, F., Rambaldi, A., Barosi, G., Rosen, P.J., He, S., Contel, N., Mookerjee, B., Rumi, E., Gattoni, E., Pieri, L., Cazzola, M., Kantarjian, H.M., Barbui, T. & Vannucchi, A.M. (2012a) Long-term efficacy and safety results from a phase II study of ruxolitinib in patients with polyucythemia vera. Blood (Annual Meeting Abstracts), 120, 804.
28. Verstovsek, S., Mesa, R.A., Gotlib, J., Levy, R.S., Gupta, V., DiPersio, J.F., Catalano, J.V., Deininger, M., Miller, C., Silver, R.T., Talpaz, M., Winton, E.F., Harvey, J.H. Jr, Arcasoy, M.O., Hexner, E., Lyons, R.M., Paquette, R., Raza, A., Vaddi, K., Erickson-Viitanen, S., Koumenis, I.L., Sun, W., Sandor, V. & Kantarjian, H.M. (2012b) A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. New England Journal of Medicine, 366, 799-807.
29. Wang, Y., Fiskus, W., Chong, D.G., Buckley, K.M., Natarajan, K., Rao, R., Joshi, A., Balusu, R., Koul, S., Chen, J., Savoie, A., Ustun, C., Jillella, A.P., Atadja, P., Levine, R.L. & Bhalla, K.N. (2009) Cotreatment with panobinostat and JAK2 inhibitor TG101029 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells. Blood, 114, 5024-5033.
30. Wang, X., Zhang, W., Tripodi, J., Lu, M., Xu, M., Najfeld, V., Li, Y. & Hoffman, R. (2010) Sequential treatment of CD34+ cells from patients with primary myelofibrosis with chromatin-modifying agents eliminate JAK2V617F-positive NOD/SCID marrow repopulating cells. Blood, 116, 5972-5982.